Effect of ciclosporin on safety, lymphocyte kinetics and left ventricular remodelling in acute myocardial infarction
British Journal of Clinical Pharmacology2020Vol. 86(7), pp. 1387–1397
Citations Over TimeTop 19% of 2020 papers
Suzanne Cormack, Ashfaq Mohammed, Pedram Panahi, Rajiv Das, Alison Steel, Thomas Chadwick, Andrew Bryant, Mohaned Egred, Konstantinos Stellos, Ioakim Spyridopoulos, the CAPRI investigators
Abstract
In our pilot trial, a single ciclosporin bolus did not affect infarct size or left ventricular remodelling, matching the results from CYCLE and CIRCUS. Our study suggests that ciclosporin does either not reach ischaemic cardiomyocytes, or requires earlier application during first medical contact. Finally, 1 bolus of ciclosporin is not sufficient to inhibit CD4 T-lymphocyte proliferation during remodelling. We therefore believe that further studies are warranted. (Evaluating the effectiveness of intravenous Ciclosporin on reducing reperfusion injury in pAtients undergoing PRImary percutaneous coronary intervention [CAPRI]; NCT02390674).
Related Papers
- → Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care(2015)47 cited
- → Ocular Pharmacokinetics and Safety of Ciclosporin, a Novel Topical Treatment for Dry Eye(2005)79 cited
- → Oral erosive/ulcerative lichen planus: preliminary findings in an open trial of sulodexide compared with cyclosporine (ciclosporin) therapy(2003)22 cited
- → Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis(2011)3 cited
- Ciclosporin soft capsule used in kidney transplantation patients(2000)